Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain

Salina Akter, Hiroyuki Sasaki, Kazi Rasel Uddin, Yuko Ikeda, Hiroki Miyakawa, Shigenobu Shibata

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5% in the mouse standard diet (14% casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5% GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5% GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5% GORZ treatment. Moreover, 0.5% GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5% GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.

    Original languageEnglish
    Pages (from-to)119-128
    Number of pages10
    JournalLife Sciences
    Volume216
    DOIs
    Publication statusPublished - 2019 Jan 1

    Fingerprint

    Anti-Anxiety Agents
    Brain
    Corticosterone
    Amygdala
    Body Weight
    Inbred ICR Mouse
    Hydroxyindoleacetic Acid
    Caseins
    Anxiety Disorders
    Serum
    Cerebral Cortex
    Weight Gain
    Neurotransmitter Agents
    Hippocampus
    Anxiety
    Diet
    Light
    Pharmaceutical Preparations
    Nutrition
    Metabolites

    Keywords

    • Amygdala
    • Anxiety
    • Monoamines
    • γ-oryzanol

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Pharmacology, Toxicology and Pharmaceutics(all)

    Cite this

    Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain. / Akter, Salina; Sasaki, Hiroyuki; Uddin, Kazi Rasel; Ikeda, Yuko; Miyakawa, Hiroki; Shibata, Shigenobu.

    In: Life Sciences, Vol. 216, 01.01.2019, p. 119-128.

    Research output: Contribution to journalArticle

    Akter, Salina ; Sasaki, Hiroyuki ; Uddin, Kazi Rasel ; Ikeda, Yuko ; Miyakawa, Hiroki ; Shibata, Shigenobu. / Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain. In: Life Sciences. 2019 ; Vol. 216. pp. 119-128.
    @article{0e5abc781d0d4fbdabcf7960f4f9226c,
    title = "Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain",
    abstract = "Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5{\%} in the mouse standard diet (14{\%} casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5{\%} GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5{\%} GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5{\%} GORZ treatment. Moreover, 0.5{\%} GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5{\%} GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.",
    keywords = "Amygdala, Anxiety, Monoamines, γ-oryzanol",
    author = "Salina Akter and Hiroyuki Sasaki and Uddin, {Kazi Rasel} and Yuko Ikeda and Hiroki Miyakawa and Shigenobu Shibata",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1016/j.lfs.2018.11.042",
    language = "English",
    volume = "216",
    pages = "119--128",
    journal = "Life Sciences",
    issn = "0024-3205",
    publisher = "Elsevier Inc.",

    }

    TY - JOUR

    T1 - Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain

    AU - Akter, Salina

    AU - Sasaki, Hiroyuki

    AU - Uddin, Kazi Rasel

    AU - Ikeda, Yuko

    AU - Miyakawa, Hiroki

    AU - Shibata, Shigenobu

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5% in the mouse standard diet (14% casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5% GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5% GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5% GORZ treatment. Moreover, 0.5% GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5% GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.

    AB - Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5% in the mouse standard diet (14% casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5% GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5% GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5% GORZ treatment. Moreover, 0.5% GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5% GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.

    KW - Amygdala

    KW - Anxiety

    KW - Monoamines

    KW - γ-oryzanol

    UR - http://www.scopus.com/inward/record.url?scp=85056807560&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85056807560&partnerID=8YFLogxK

    U2 - 10.1016/j.lfs.2018.11.042

    DO - 10.1016/j.lfs.2018.11.042

    M3 - Article

    VL - 216

    SP - 119

    EP - 128

    JO - Life Sciences

    JF - Life Sciences

    SN - 0024-3205

    ER -